{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"tb-500","urls":{"read":"https://miscsubjects.com/api/articles/tb-500/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/tb-500/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/tb-500/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/tb-500/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/tb-500/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/tb-500/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/tb-500/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"tb-500","title":"TB-500 (Thymosin Beta-4)","register":"essay","tags":["peptide","tb-500","thymosin-beta-4","disc"],"updated_at":"2026-07-24T17:41:57.461Z","body_excerpt":"TB-500 is sold as a healing peptide, and the first thing to understand is that \"TB-500\" and the peptide in the actual research trials are usually not the same molecule. The trials used full-length thymosin beta-4 (Tβ4), a 43-amino-acid protein the body makes in nearly every tissue. Most vials sold as \"TB-500\" contain a synthetic fragment — the acetylated seven-amino-acid piece (Ac-LKKTETQ) that holds the actin-binding activity — chosen because it's cheaper to make. That single fact reshapes how you should read every efficacy and safety claim below. This page covers what Tβ4 actually does, what has and hasn't been shown in humans, the fragment problem, real dosing and reconstitution, the cancer question that defines its risk, its ban in sport, and where it sits in a disc-recovery stack. Zero prior knowledge assumed.\n\n## What it actually is\n\nThymosin beta-4 is the body's main G-actin-sequestering peptide. Actin is the protein a cell uses to build and tear down its internal skeleton; controlling that is how a cell changes shape and crawls. Tβ4 binds actin monomers one-to-one and regulates that machinery, which is why it shows up wherever tissue is rebuilding — wounds, healing heart, migrating repair cells.\n\n## TB-500 is not thymosin beta-4 — read this before anything else\n\nThe distinction is routinely buried by vendors and it is central:\n\n- **Thymosin beta-4 (Tβ4):** the full 43-amino-acid protein used in every legitimate human and animal trial (IV cardiac, RGN-259 eye drops, wound studies).\n- **\"TB-500\":** a marketed synthetic fragment, the acetylated heptapeptide Ac-LKKTETQ (residues 17-23, ~889 Da), sold as a stable, cheaper stand-in. It reproduces the actin-binding activity but is not the molecule trialed clinically.\n\n[[embed:source:s17]]\n\nTo make it worse, full-length Tβ4 is also cleaved in the body to a different active fragment (Ac-SDKP), and some products sold as \"TB-500\" actually contain that instead. So \"TB-500\" is not even one consistent substance across vendors — you often cannot know which molecule you received. Efficacy and safety data for full Tβ4 cannot simply be assumed to transfer to whatever is in the vial.\n\n## One short motif does the healing\n\nThe repair-relevant part of Tβ4 is that seven-amino-acid actin-binding motif, and the same motif drives angiogenesis and endothelial cell migration — the growth of new blood vessels.\n\n[[embed:source:s1]]\n\nThat matters for a disc because tendon, ligament, and disc are poorly vascularized, and blood supply is the rate-limiter on healing them. A repair mechanism that is intrinsically pro-angiogenic is aimed straight at that bottleneck. On paper.\n\n## The human record: one clear win, several honest misses\n\nIn animal wound models the effect is clean — topical or systemic Tβ4 sped skin regrowth by 42-61% while adding collagen and vessels.\n\n[[embed:source:s2]]\n\nIn humans, full Tβ4 went into proper randomized, placebo-controlled trials for chronic wounds (pressure ulcers, venous stasis ulcers). Honest result: safe and well tolerated, but the primary healing endpoints did not reach statistical significance.\n\n[[embed:source:s3]]\n\nThe one indication where human data turned clearly positive is the eye. The ophthalmic formulation RGN-259 significantly improved dry-eye signs and symptoms versus placebo in Phase 2 trials.\n\n[[embed:source:s18]]\n\nSo the truthful summary is narrow: one positive human indication (dry eye), wound trials that were safe but unproven, and — for tendon, ligament, muscle, and disc — no confirmatory human trial at all.\n\n[[embed:source:s10]]\n\n## Heart, stroke, ligament: the preclinical case\n\nThe animal repair record is broad and consistent with the mechanism. After a heart attack, Tβ4 given locally and systemically shrank infarct size and improved function via cell-survival pathways (ILK/Akt) with less scarring — and the systemic result matters, because it shows the peptide reaches a distant injury and acts there.\n\n[[embed:source:s9]]\n\nIn a rat embolic stroke it im","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c4","text":"Tb4 reached genuine randomized, double-blind, placebo-controlled human trials for chronic wounds (pressure and venous stasis ulcers), where it was safe but did not hit statistical significance on primary healing endpoints.","tier":"human","interaction_risk":false,"status":"active","source_ids":["s3","s4","s5"],"why_material":"Separates 'has real human trials' from 'proven to work in humans'.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c5","text":"The ophthalmic Tb4 formulation RGN-259 showed positive Phase II human efficacy for dry-eye signs and symptoms via corneal epithelial repair — the strongest controlled human efficacy signal for the peptide.","tier":"human","interaction_risk":false,"status":"active","source_ids":["s7"],"why_material":"The one indication with positive human RCT data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c8","text":"Across multiple chronic human wound types Tb4 has been reported to promote faster repair, extending its regenerative case into diseased human tissue.","tier":"human","interaction_risk":false,"status":"active","source_ids":["s13"],"why_material":"Broadens human regeneration evidence beyond one indication.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c9","text":"TB-500 and thymosin beta-4 are on the WADA Prohibited List and banned at all times for competitive athletes.","tier":"human","interaction_risk":false,"status":"active","source_ids":["s12"],"why_material":"Mandatory compliance flag for anyone in tested sport.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"In controlled animal wound models, Tb4 accelerated skin regeneration (reepithelialization up 42-61%) while increasing collagen deposition and angiogenesis.","tier":"preclinical","interaction_risk":false,"status":"active","source_ids":["s2"],"why_material":"Quantified placebo-controlled preclinical anchor.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c6","text":"In preclinical cardiac injury, both local and systemic Tb4 dosing reduced infarct size and improved function via cardiomyocyte survival (ILK/Akt) and angiogenesis.","tier":"preclinical","interaction_risk":false,"status":"active","source_ids":["s8","s9"],"why_material":"Shows anti-fibrotic regeneration and that systemic dosing reaches injury sites — the assumption behind injectable TB-500.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c7","text":"Tb4 improved ligament healing histologically and mechanically in a rat MCL model, but a 2026 scoping review confirms tendon, ligament, muscle and spine/disc evidence remains overwhelmingly animal-stage with no confirmatory human musculoskeletal trials.","tier":"preclinical","interaction_risk":false,"status":"active","source_ids":["s11","s10"],"why_material":"Gives the real promising-but-unproven status for the exact tissue class the disc stack targets.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c1","text":"TB-500 is a synthetic version of thymosin beta-4, the body's principal G-actin-sequestering peptide, which regulates the actin dynamics that govern cell migration — the molecular basis for its role in tissue repair.","tier":"mechanistic","interaction_risk":false,"status":"active","source_ids":["s1","s4"],"why_material":"Establishes the mechanistic basis for every regeneration claim.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c2","text":"The same seven-amino-acid actin-binding motif that gives Tb4 its structural function also drives angiogenesis and endothelial migration, so new blood-vessel growth is intrinsic to how it repairs tissue.","tier":"mechanistic","interaction_risk":false,"status":"active","source_ids":["s1"],"why_material":"Angiogenesis is the rate-limiter for healing poorly-vascularized tendon, ligament and disc.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c10","text":"Real-world users self-treating tendon, tendinitis and spine/sacral injuries with TB-500 (usually stacked with BPC-157) report reduced pain and improved range of motion, but these are uncontrolled, confounded anecdotes.","tier":"anecdotal","interaction_risk":false,"status":"active","source_ids":["s14","s15","s16"],"why_material":"Captures the following for the disc/tendon use-case while firewalling anecdote from trial data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/14500546/","title":"The actin binding site on thymosin beta4 promotes angiogenesis","quote":"we find that a seven amino acid actin binding motif of thymosin beta4 is essential for its angiogenic activity.","claim_ids":["c1","c2"]},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/10469335/","title":"Thymosin beta4 accelerates wound healing","quote":"Addition of Tbeta4 topically or intraperitoneally increased reepithelialization by 42% over saline controls at 4 d and by as much as 61% at 7 d post-wounding.","claim_ids":["c3"]},{"id":"s3","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT00382174","title":"Randomized, Double-Blind, Placebo-Controlled Study of Thymosin Beta 4 in Patients With Pressure Ulcers","quote":"evaluate the safety, tolerability and effectiveness of Thymosin Beta 4 administered topically in patients with Pressure Ulcers","claim_ids":["c4"]},{"id":"s4","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT00832091","title":"Randomized, Double-Blind, Placebo-Controlled Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers","quote":"a synthetically-produced copy of a naturally occurring 43 amino acid peptide that has wound healing and anti-inflammatory properties and can up-regulate the expression of laminin-5.","claim_ids":["c1","c4"]},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/17495250/","title":"Thymosin beta-4 and venous ulcers: a European prospective, randomized study","quote":"When review safety data show no-dose-limiting adverse events, a new group will be enrolled.","claim_ids":["c4"]},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/26056426/","title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial","quote":"This study confirms the efficacy of 0.1% Tbeta4 as a topical treatment for relief of signs and symptoms of dry eye.","claim_ids":["c5"]},{"id":"s8","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3843122/","title":"Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury","quote":"Tbeta4 administered throughout the study reduced infarct size and resulted in significant improvements in hemodynamic performance.","claim_ids":["c6"]},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/17600280/","title":"Thymosin beta4 is cardioprotective after myocardial infarction","quote":"thymosin beta4 treatment resulted in upregulation of ILK and Akt activity in the heart, enhanced early myocyte survival, and improved cardiac function.","claim_ids":["c6"]},{"id":"s10","type":"pubmed","url":"https://doi.org/10.3390/app16126202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review","quote":"the evidence base is heavily weighted toward preclinical and mechanistic work, with human musculoskeletal data sparse","claim_ids":["c7"]},{"id":"s11","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/23523891/","title":"Thymosin beta4 enhances the healing of medial collateral ligament injury in rat","quote":"Local administration of Tbeta4 promotes the healing process of MCL, both histologically and mechanically, in a rat model.","claim_ids":["c7"]},{"id":"s12","type":"news","url":"https://www.bscg.org/blogs/single/tb-500-status-risks-and-bans-in-sport-and-military","title":"TB-500 - Status, Risks, and Bans in Sport and Military","quote":"The World Anti-Doping Agency (WADA) lists TB-500 under 'Growth Factors and Growth Factor Modulators' as a prohibited substance","claim_ids":["c9"]},{"id":"s13","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31649007/","title":"Thymosin beta4: potential to treat epidermolysis bullosa and other severe dermal injuries","quote":"Thymosin beta4 promotes faster repair in various chronic human wounds, including pressure ulcers, stasis ulcers, and epidermolysis bullosa lesions.","claim_ids":["c8"]},{"id":"s14","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/ypyy1v/initial_impressions_with_bpc157_and_tb500_for/","title":"Initial impressions with BPC-157 and TB-500 for tendon repair","quote":"Inflammation and pain is significantly reduced. ROM is improving for repaired bicep. Unfortunately no control for comparison.","claim_ids":["c10"]},{"id":"s15","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1cnx3vj/bpc_157_tb_500_tendinitis_experience/","title":"BPC 157 / TB 500 tendinitis experience","quote":"I would strongly and without reservation recommend this combo to anyone with tendinitis. Remember that you still have to do the work though!","claim_ids":["c10"]},{"id":"s16","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/sjml9z/my_story_and_bpc157tb500_ghrp2_observations_so_far/","title":"My story and BPC-157/TB-500, GHRP-2 observations so far","quote":"chronic pain without trauma or known cause since 1 year ago. Started out in my sacrum (specifically S5 segment)","claim_ids":["c10"]},{"id":"s17","type":"news","url":"https://www.bscg.org/blogs/single/tb-500-status-risks-and-bans-in-sport-and-military","title":"TB-500 - Status, Risks, and Bans (BSCG)","quote":"TB-500 is a synthetic heptapeptide (Ac-LKKTETQ) that corresponds to amino acids 17-23 of thymosin beta-4","claim_ids":[]},{"id":"s18","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/25826322/","title":"Thymosin beta4 improves signs and symptoms of severe dry eye in a phase 2 randomized trial (Cornea 2015)","quote":"RGN-259-treated group had 35.1% reduction of ocular discomfort compared with vehicle control (P = 0.0141)","claim_ids":[]},{"id":"s19","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20627173/","title":"Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke","quote":"Tbeta4 improves neurological functional outcome after embolic stroke in rats.","claim_ids":[]},{"id":"s20","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/14625258/","title":"Role of thymosin beta4 in tumor metastasis and angiogenesis (JNCI 2003)","quote":"Thymosin beta4 may stimulate tumor metastasis by activating cell migration and angiogenesis.","claim_ids":[]},{"id":"s21","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/19833631/","title":"Thymosin beta4 has tumor suppressive effects in multiple myeloma","quote":"Tbeta4 overexpression led to significantly decreased proliferative and migratory capacities and increased sensitivity to apoptosis-induction.","claim_ids":[]}],"anecdotal_sources":[{"id":"s14","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/ypyy1v/initial_impressions_with_bpc157_and_tb500_for/","title":"Initial impressions with BPC-157 and TB-500 for tendon repair","quote":"Inflammation and pain is significantly reduced. ROM is improving for repaired bicep. Unfortunately no control for comparison.","claim_ids":["c10"]},{"id":"s15","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1cnx3vj/bpc_157_tb_500_tendinitis_experience/","title":"BPC 157 / TB 500 tendinitis experience","quote":"I would strongly and without reservation recommend this combo to anyone with tendinitis. Remember that you still have to do the work though!","claim_ids":["c10"]},{"id":"s16","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/sjml9z/my_story_and_bpc157tb500_ghrp2_observations_so_far/","title":"My story and BPC-157/TB-500, GHRP-2 observations so far","quote":"chronic pain without trauma or known cause since 1 year ago. Started out in my sacrum (specifically S5 segment)","claim_ids":["c10"]}],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/14500546/","title":"The actin binding site on thymosin beta4 promotes angiogenesis","quote":"we find that a seven amino acid actin binding motif of thymosin beta4 is essential for its angiogenic activity.","claim_ids":["c1","c2"]},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/10469335/","title":"Thymosin beta4 accelerates wound healing","quote":"Addition of Tbeta4 topically or intraperitoneally increased reepithelialization by 42% over saline controls at 4 d and by as much as 61% at 7 d post-wounding.","claim_ids":["c3"]},{"id":"s3","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT00382174","title":"Randomized, Double-Blind, Placebo-Controlled Study of Thymosin Beta 4 in Patients With Pressure Ulcers","quote":"evaluate the safety, tolerability and effectiveness of Thymosin Beta 4 administered topically in patients with Pressure Ulcers","claim_ids":["c4"]},{"id":"s4","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT00832091","title":"Randomized, Double-Blind, Placebo-Controlled Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers","quote":"a synthetically-produced copy of a naturally occurring 43 amino acid peptide that has wound healing and anti-inflammatory properties and can up-regulate the expression of laminin-5.","claim_ids":["c1","c4"]},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/17495250/","title":"Thymosin beta-4 and venous ulcers: a European prospective, randomized study","quote":"When review safety data show no-dose-limiting adverse events, a new group will be enrolled.","claim_ids":["c4"]},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/26056426/","title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial","quote":"This study confirms the efficacy of 0.1% Tbeta4 as a topical treatment for relief of signs and symptoms of dry eye.","claim_ids":["c5"]},{"id":"s8","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3843122/","title":"Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury","quote":"Tbeta4 administered throughout the study reduced infarct size and resulted in significant improvements in hemodynamic performance.","claim_ids":["c6"]},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/17600280/","title":"Thymosin beta4 is cardioprotective after myocardial infarction","quote":"thymosin beta4 treatment resulted in upregulation of ILK and Akt activity in the heart, enhanced early myocyte survival, and improved cardiac function.","claim_ids":["c6"]},{"id":"s10","type":"pubmed","url":"https://doi.org/10.3390/app16126202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review","quote":"the evidence base is heavily weighted toward preclinical and mechanistic work, with human musculoskeletal data sparse","claim_ids":["c7"]},{"id":"s11","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/23523891/","title":"Thymosin beta4 enhances the healing of medial collateral ligament injury in rat","quote":"Local administration of Tbeta4 promotes the healing process of MCL, both histologically and mechanically, in a rat model.","claim_ids":["c7"]},{"id":"s13","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31649007/","title":"Thymosin beta4: potential to treat epidermolysis bullosa and other severe dermal injuries","quote":"Thymosin beta4 promotes faster repair in various chronic human wounds, including pressure ulcers, stasis ulcers, and epidermolysis bullosa lesions.","claim_ids":["c8"]},{"id":"s18","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/25826322/","title":"Thymosin beta4 improves signs and symptoms of severe dry eye in a phase 2 randomized trial (Cornea 2015)","quote":"RGN-259-treated group had 35.1% reduction of ocular discomfort compared with vehicle control (P = 0.0141)","claim_ids":[]},{"id":"s19","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20627173/","title":"Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke","quote":"Tbeta4 improves neurological functional outcome after embolic stroke in rats.","claim_ids":[]},{"id":"s20","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/14625258/","title":"Role of thymosin beta4 in tumor metastasis and angiogenesis (JNCI 2003)","quote":"Thymosin beta4 may stimulate tumor metastasis by activating cell migration and angiogenesis.","claim_ids":[]},{"id":"s21","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/19833631/","title":"Thymosin beta4 has tumor suppressive effects in multiple myeloma","quote":"Tbeta4 overexpression led to significantly decreased proliferative and migratory capacities and increased sensitivity to apoptosis-induction.","claim_ids":[]}],"user_reports":[],"related_articles":[{"slug":"the-disc-stack","title":"The Disc Recovery Stack","claims":[{"id":"c1","text":"The disc is the body's largest avascular structure and repairs poorly on its own, which is the central obstacle any disc-recovery strategy must overcome.","tier":"mechanistic"},{"id":"c2","text":"The body already removes most herniations: ~67% resorb spontaneously via a macrophage- and blood-vessel-driven process, so recovery means supporting an existing mechanism, not forcing a new one.","tier":"human"},{"id":"c3","text":"Body weight is a modifiable driver: overweight and obesity raise the odds of sciatica and disc herniation, making load reduction the one lever a person directly controls.","tier":"human"},{"id":"c4","text":"TNF-alpha and IL-1beta drive both disc degeneration and the inflammatory nerve pain of a herniation, making the inflammatory signal a shared target.","tier":"mechanistic"},{"id":"c5","text":"A human meta-analysis found stem-cell injection may reduce discogenic pain and disability, the first real human signal that the disc is a regeneration target - though still small and early.","tier":"human"}]},{"slug":"bpc-157","title":"BPC-157: Body Protection Compound","claims":[{"id":"c1","text":"BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.","tier":"human"},{"id":"c2","text":"Over 100 animal and cell studies report accelerated healing parameters such as improved collagen organization and vascular ingrowth in tendon, gut, muscle, bone, and nerve models.","tier":"preclinical"},{"id":"c3","text":"A 2025 pilot study found intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subjective reports.","tier":"human"},{"id":"c4","text":"Proposed actions include promotion of local angiogenesis and interaction with nitric oxide pathways in damaged tissue.","tier":"mechanistic"},{"id":"c5","text":"One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).","tier":"anecdotal"},{"id":"c6","text":"One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).","tier":"anecdotal"},{"id":"c7","text":"One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1).","tier":"anecdotal"},{"id":"c8","text":"One user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).","tier":"anecdotal"}]},{"slug":"ara-290","title":"ARA-290 (Cibinetide)","claims":[{"id":"c1","text":"ARA-290 (cibinetide) is an 11-amino-acid peptide from EPO's helix-B surface that activates the innate repair receptor (EPOR/beta-common heterocomplex) to drive tissue repair, distinct from EPO's erythropoietic receptor.","tier":"mechanistic"},{"id":"c2","text":"Because it engages the innate repair receptor rather than the homodimeric EPO receptor, ARA-290 does not stimulate erythropoiesis or raise hematocrit, avoiding EPO's thrombotic risk.","tier":"mechanistic"},{"id":"c3","text":"The mechanism was defined by Michael Brines and Anthony Cerami, who showed EPO's tissue protection runs through an EPOR/beta-common-receptor heterocomplex.","tier":"mechanistic"},{"id":"c4","text":"In a randomized, double-blind, placebo-controlled pilot in sarcoidosis patients with small-fiber neuropathy, ARA 290 significantly improved neuropathy symptom scores versus placebo.","tier":"human"},{"id":"c5","text":"In a Phase 2b RCT (n=64), 4 mg/day cibinetide significantly increased corneal nerve fiber area and raised GAP-43+ regenerating intraepidermal nerve fibers, an objective structural sign of nerve regeneration.","tier":"human"},{"id":"c6","text":"In type 2 diabetics, ARA 290 improved neuropathic symptoms alongside HbA1c and lipids over 56 days without safety issues.","tier":"human"},{"id":"c7","text":"In nerve-injury models, ARA 290 produced long-lasting, dose-dependent reductions in allodynia coupled to suppression of the spinal microglial neuroinflammatory response.","tier":"preclinical"},{"id":"c8","text":"ARA 290 inhibits macrophage activation and pro-inflammatory cytokine release (IL-6, IL-12, TNF-alpha) and protects cells from cytokine-induced apoptosis.","tier":"preclinical"}]},{"slug":"retatrutide","title":"Retatrutide","claims":[{"id":"rc-mech","text":"Retatrutide is a single synthetic peptide that agonizes three receptors at once — GLP-1, GIP, and glucagon (GCGR).","tier":"mechanistic"},{"id":"rc-mech2","text":"Glucagon-receptor agonism raises energy expenditure and hepatic fat oxidation, adding an energy-output arm on top of the appetite-suppressing GLP-1/GIP arms.","tier":"mechanistic"},{"id":"rc-obesity","text":"In adults with obesity, meta-analysis finds retatrutide produces large, dose-dependent body-weight reductions, statistically and clinically superior to placebo, with the highest doses approaching ~24% at ~48 weeks.","tier":"human"},{"id":"rc-t2d","text":"In type 2 diabetes, a Phase 2 substudy found retatrutide significantly improved total body-fat-mass reduction versus both placebo and dulaglutide.","tier":"human"},{"id":"rc-safety","text":"Adverse events are the dose-dependent incretin profile — nausea, diarrhea, vomiting; a safety review found the profile acceptable but did not establish long-term safety.","tier":"human"},{"id":"rc-phase3","text":"The Phase 3 TRIUMPH program is ongoing and retatrutide is not approved by any regulator as of writing; everything here is investigational trial data.","tier":"system"},{"id":"rc-ruo","text":"This is a research-use-only compound. The article reports trial data; it is not medical advice and does not establish a treatment for any person.","tier":"system"}]},{"slug":"herniated-disc","title":"Herniated Disc","claims":[{"id":"c1","text":"A herniated disc is not a broken part but displaced tissue: the gel-like nucleus pulposus pushes through a tear in the annulus fibrosus, usually posterolaterally where the annulus is thinnest, contacting the nerve root.","tier":"mechanistic"},{"id":"c2","text":"Most herniated discs spontaneously resorb: pooled data put overall resorption at roughly two-thirds of cases under conservative care.","tier":"human"},{"id":"c3","text":"Counterintuitively, the biggest herniations resorb best: extruded and sequestered fragments are significantly more likely to fully regress than small contained bulges.","tier":"human"},{"id":"c4","text":"Resorption is an active immune-regenerative process: macrophages infiltrate the extruded nucleus pulposus, phagocytose it, and trigger enzymes and new blood-vessel growth that dissolve the fragment.","tier":"mechanistic"},{"id":"c5","text":"The disc heals slowly because mature disc tissue is nearly avascular; recovery hinges on neovascularization at the herniation edge, driven by VEGF, bringing blood supply where there normally is none.","tier":"mechanistic"},{"id":"c6","text":"Sciatic/radicular pain is largely chemical, not just mechanical: nucleus pulposus releases TNF-alpha and extraordinarily high phospholipase A2 activity that inflame and sensitize the nerve root.","tier":"preclinical"},{"id":"c7","text":"Pain relief typically precedes and outpaces imaging resorption: patients often become functional in weeks while the fragment shrinks over months.","tier":"human"},{"id":"c8","text":"Surgery speeds early relief but is not required for most: in the randomized SPORT trial both surgical and non-surgical patients improved substantially over two years.","tier":"human"}]}],"question_graph":{"slug":"tb-500","questions":[{"node_id":"qn_tb_500_selftest_graph_what_is_documented_about_t_5f127446","ts":"2026-07-11T14:38:52.399Z","primary_slug":"tb-500","slugs":["tb-500"],"question":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","answer_preview":"Documented TB-500 mechanism in the ledger (no new evidence): TB-500 (fragment of thymosin beta-4) binds free G-actin inside cells, freeing actin monomers for new filament assembly at the leading edge; this enables cell migration toward injury sites, release of signals supporting new vessel formation, and reduction of excess inflammation, resulting in faster wound re-closure and repair matrix deposition in animal models. Core claim: Tβ4 promotes cell migration, angiogenesis, and modulates inflammation via actin sequestration (c1, s1). Preclinical support includes rat full-thickness wound models showing accelerated re-epithelialization (c2, s2). Human data are limited to safety (c3, s3) and specific wound-healing trials (c4, s4); no new mechanistic evidence is present.","confidence":"high","status":"answered","parent_node_id":null,"gaps":[],"needs_user_info":[],"cited_claim_ids":["c1","c2","c3","c4"],"cited_source_ids":["s1","s2","s3","s4"],"channel":"selftest","author":"graph_selftest","hash":"390da20d84640e5b48bd7c8dbfe6333b645fee1429f06acadaf67bbe59dd4e77"},{"node_id":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_241eb02b","ts":"2026-07-11T14:38:41.428Z","primary_slug":"bpc-157","slugs":["bpc-157","recovery-stack-herniated-disc","bpc-ara-herniated-disc","ara-290-herniated-disc","tb-500","ara-290","recovery-stack-intro"],"question":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","answer_preview":"The catalogue lists three tiers of herniated-disc anecdotes for BPC-157: (1) one Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 plus physical therapy (global_id bpc-157:c5, tier=anecdotal, weight=0.3); (2) several self-test posts describe reduced back or knee pain after eight weeks but include no imaging follow-up (bpc-157 section “What people say on Reddit”); (3) duplicate nausea reports (multiple instances of the same anecdote, each labeled anecdotal n=1, weight=0.3). No other slugs in the topology contain herniated-disc anecdotes. All listed items are pre-ranked as low-weight anecdotal claims; interaction_risk / limitations claims (c120, c67) are cited first per safety-first ordering.","confidence":"medium","status":"enriched","parent_node_id":null,"gaps":["No imaging-confirmed outcomes; no long-term follow-up; no interaction data specific to herniated-disc patients or common spine medications."],"needs_user_info":[],"cited_claim_ids":["c5","c120","c67"],"cited_source_ids":[],"channel":"selftest","author":"graph_selftest","hash":"48f991e2315a93cbf21a35b1c623cef22caf053ca87390f380aa6bfe85563d5a"},{"node_id":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_50c640ac","ts":"2026-07-11T14:38:17.208Z","primary_slug":"bpc-157","slugs":["bpc-157","recovery-stack-herniated-disc","bpc-ara-herniated-disc","ara-290-herniated-disc","tb-500","ara-290","recovery-stack-intro"],"question":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","answer_preview":"Catalogue covers BPC-157 (bpc-157) and TB-500 (tb-500) in the context of herniated-disc recovery. One anecdotal claim (global_id recovery-stack-herniated-disc:c5) describes a single user reporting reduced radicular pain after 8 weeks of BPC-157 plus physical therapy for L4-L5 herniation. Additional anecdotal claims note BPC-157/TB-500 combinations for systemic tissue and tendon healing (bpc-157:c111). Limitations claims state human data are sparse, long-term safety unknown, and no dosing or protocol recommendations exist (bpc-157:c120, c67). No dedicated stack articles for herniated discs appear in the topology beyond the intro and BPC/TB-500 mentions.","confidence":"low","status":"enriched","parent_node_id":null,"gaps":["No controlled human trials for herniated-disc outcomes","No data on BPC-157/TB-500 interactions or safety in disc pathology","No coverage of other peptides (e.g., ARA-290) for herniated discs in the provided slugs"],"needs_user_info":[],"cited_claim_ids":["bpc-157:c5","bpc-157:c111","bpc-157:c120","bpc-157:c67"],"cited_source_ids":[],"channel":"selftest","author":"graph_selftest","hash":"44acb22aa47103bebdd2e83cff2f68f753634aae351dc69043ce6e762dc28117"},{"node_id":"qn_tb_500_selftest_graph_what_is_documented_about_t_1b217ea4","ts":"2026-07-07T05:18:10.136Z","primary_slug":"tb-500","slugs":["tb-500"],"question":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","answer_preview":"Documented mechanism from the ledger: TB-500 (Tβ4 fragment) binds free G-actin inside cells, freeing actin monomers for new filament assembly at the leading edge; this enables cell migration toward injury sites, release of signals supporting new vessel formation, and modulation of inflammation, leading to faster wound re-closure and repair matrix deposition in animal models. Core claims: c1 (actin sequestration, cell migration, angiogenesis, inflammation modulation; tier human, source s1), c3 (Phase 1 IV safety/tolerability in healthy volunteers; tier human, source s3), c4 (Phase 2 topical acceleration in some stasis/pressure ulcer patients; tier human, source s4), c2 (rat wound re-epithelialization increase; tier preclinical, source s2). No new evidence; human data sparse, most evidence preclinical or anecdotal. Quote-gated claims (e.g., c6, c13, c16, c27, c40, c41, c42, c46) treated as low-confidence. No interaction_risk/limitations claims present in the provided topology.","confidence":"medium","status":"gap","parent_node_id":null,"gaps":["No interaction_risk or limitations-slot claims available","No dosing, patient-specific, or combination safety data","Human orthopaedic and systemic data lacking per s6"],"needs_user_info":[],"cited_claim_ids":["c1","c3","c4","c2"],"cited_source_ids":["s1","s3","s4","s2"],"channel":"selftest","author":"graph_selftest","hash":"f841cae37d5443fc5dd3d9e65c256f4421e08a358874306957f6cbb824e53bda"},{"node_id":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_7d3887e7","ts":"2026-07-07T05:18:02.500Z","primary_slug":"bpc-157","slugs":["bpc-157","recovery-stack-herniated-disc","bpc-ara-herniated-disc","ara-290-herniated-disc","tb-500","ara-290","recovery-stack-intro"],"question":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","answer_preview":"Catalogue lists one direct herniated-disc anecdote: c5 (global_id bpc-157:c5) — one Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 plus PT (anecdotal, n=1, tier=anecdotal, weight=0.3). Additional anecdotes exist for tendon/muscle/gut issues (e.g., c101, c111) but are not disc-specific. No interaction_risk or limitations-slot claims appear for herniated discs. Multiple duplicate nausea reports (c6, c122–c162) are catalogued as anecdotal negative outcomes.","confidence":"medium","status":"enriched","parent_node_id":null,"gaps":["No controlled human data for herniated discs; anecdotes are n=1, self-reported, no imaging follow-up."],"needs_user_info":[],"cited_claim_ids":["bpc-157:c5","bpc-157:c6","bpc-157:c101","bpc-157:c111"],"cited_source_ids":[],"channel":"selftest","author":"graph_selftest","hash":"9e2dce074b1cc5ba18ae5541e0c30d9b36bbe047f91880ce0470704a828b6545"},{"node_id":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_5f30a319","ts":"2026-07-07T05:17:49.886Z","primary_slug":"bpc-157","slugs":["bpc-157","recovery-stack-herniated-disc","bpc-ara-herniated-disc","ara-290-herniated-disc","tb-500","ara-290","recovery-stack-intro"],"question":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","answer_preview":"Catalogue covers: BPC-157 (preclinical tendon/muscle/gut models + 1 anecdotal L4-L5 herniation report of reduced radicular pain after 8 weeks with PT — c5:bpc-157); BPC-157 + TB-500 anecdotal stack for systemic tissue/tendon healing (c111:bpc-157); recovery-stack-herniated-disc and bpc-ara-herniated-disc slugs exist but contain no populated claims in the provided topology. Gaps: no human trials, no imaging outcomes, no interaction_risk data, no ARA-290 or TB-500 standalone herniated-disc claims, long-term safety unknown (c67:bpc-157), and all human evidence is sparse/pilot only. No dosing or treatment information is present.","confidence":"medium","status":"enriched","parent_node_id":null,"gaps":["no human controlled data for disc herniation","no interaction data","no ARA-290 or TB-500 herniated-disc coverage in topology","long-term safety absent"],"needs_user_info":["specific disc levels and symptoms","current medications or conditions","prior treatments tried"],"cited_claim_ids":["c5","c67","c111","c120"],"cited_source_ids":[],"channel":"selftest","author":"graph_selftest","hash":"55704c06abb3c3fee07a6aa6e20c9ff75edf4e45de4cabd4e5e735d720ee1168"},{"node_id":"qn_tb_500_selftest_graph_what_is_documented_about_t_6e5d6ef8","ts":"2026-07-07T04:40:45.011Z","primary_slug":"tb-500","slugs":["tb-500"],"question":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","answer_preview":"Documented mechanism of TB-500 (Tβ4 fragment) in the ledger: binds free G-actin, sequesters it, frees monomers for new filament assembly at the leading edge of cells, enabling cell migration to injury sites; migrating cells then release signals supporting angiogenesis and reduced excess inflammation, leading to faster wound re-closure and repair-matrix deposition in animal models. Core claim supported by review source s1 (c1) and mechanistic description in the body; no new evidence added. Safety-first: no interaction_risk or limitations-slot claims present for mechanism. All human data remain sparse; most evidence preclinical or anecdotal.","confidence":"high","status":"answered","parent_node_id":null,"gaps":[],"needs_user_info":[],"cited_claim_ids":["c1"],"cited_source_ids":["s1"],"channel":"selftest","author":"graph_selftest","hash":"ca930d58df03f2cb35e1c68fff036bee705821cfb7cfd8685a2742879f4a3cb0"},{"node_id":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_4527b1d6","ts":"2026-07-07T04:40:41.667Z","primary_slug":"bpc-157","slugs":["bpc-157","recovery-stack-herniated-disc","bpc-ara-herniated-disc","ara-290-herniated-disc","tb-500","ara-290","recovery-stack-intro"],"question":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","answer_preview":"The catalogue lists two BPC-157 herniated-disc anecdotes (global_id bpc-157:c5 and bpc-157:c6). c5 is a single Reddit-style self-report of reduced radicular pain after 8 weeks with PT (tier:anecdotal, weight 0.3). c6 is a single self-report of nausea leading to discontinuation (tier:anecdotal, weight 0.3). No other herniated-disc anecdotes appear in the listed slugs. Interaction_risk / limitations claims (bpc-157:c120, bpc-157:c67) are present and should be cited first for safety questions. All anecdotes are quote_gated:false but carry low weight; the topology contains no controlled human data on disc herniation.","confidence":"medium","status":"gap","parent_node_id":null,"gaps":["No human imaging follow-up data","No controlled trials for disc herniation","Long-term safety unknown"],"needs_user_info":[],"cited_claim_ids":["bpc-157:c5","bpc-157:c6","bpc-157:c120","bpc-157:c67"],"cited_source_ids":[],"channel":"selftest","author":"graph_selftest","hash":"1f4bcadeebf10d15569dc3a4292ca98c8dde8cf468081be16de33381f7c82677"},{"node_id":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","ts":"2026-07-07T04:40:36.928Z","primary_slug":"bpc-157","slugs":["bpc-157","recovery-stack-herniated-disc","bpc-ara-herniated-disc","ara-290-herniated-disc","tb-500","ara-290","recovery-stack-intro"],"question":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","answer_preview":"The catalogue covers BPC-157 (slug bpc-157) and TB-500 (slug tb-500) plus recovery-stack articles (recovery-stack-herniated-disc, recovery-stack-intro, bpc-ara-herniated-disc, ara-290-herniated-disc) that mention these peptides for herniated-disc contexts. Evidence is almost entirely preclinical (rat tendon/muscle models) or anecdotal (one L4-L5 herniation report of reduced radicular pain after 8 weeks BPC-157 + PT; several nausea reports leading to discontinuation). No human RCTs for disc herniation exist in the topology. Interaction_risk / limitations claims (c120, c67) must be cited first: long-term human safety unknown, no dosing data, source monoculture problem, and the catalogue is not medical advice. Gaps: no data on stacking BPC-157 with ARA-290 or other peptides for discs; no imaging-confirmed outcomes; no interaction data with common pain meds or spine conditions.","confidence":"low","status":"gap","parent_node_id":null,"gaps":["no human disc-herniation trials","no established stacks for herniated discs","no long-term safety data","no interaction data"],"needs_user_info":["specific disc levels and symptoms","current medications or conditions","prior treatments tried","imaging confirmation status"],"cited_claim_ids":["c120","c67","c5","c6","c1","c3","c30","c76"],"cited_source_ids":["s1","s3","s25","s58"],"channel":"selftest","author":"graph_selftest","hash":"83de4fe0d8850210706f9d181577d6dcc5db3b3924205aa92f57691761648ca6"},{"node_id":"qn_tb_500_selftest_graph_what_is_documented_about_t_db376414","ts":"2026-07-07T04:09:37.854Z","primary_slug":"tb-500","slugs":["tb-500"],"question":"SELFTEST GRAPH — What is documented about TB-500 mechanism in the ledger (no new evidence)?","answer_preview":"Documented mechanism from ledger: TB-500 (Tβ4 fragment) binds free G-actin, frees monomers for new filament assembly at the leading edge, enabling cell migration toward injury; migrating cells then release signals supporting new vessel formation and reducing excess inflammation, producing faster wound re-closure and repair-matrix deposition in animal models (c1, c2). No new evidence supplied; all claims drawn from existing topology only.","confidence":"high","status":"answered","parent_node_id":null,"gaps":[],"needs_user_info":[],"cited_claim_ids":["c1","c2"],"cited_source_ids":["s1","s2"],"channel":"selftest","author":"graph_selftest","hash":"b1e365a5ed961e77d4068eb344b4c787ee12d164491e69dd083843ac4717acb2"},{"node_id":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_cb92603c","ts":"2026-07-07T04:09:35.082Z","primary_slug":"bpc-157","slugs":["bpc-157","recovery-stack-herniated-disc","bpc-ara-herniated-disc","ara-290-herniated-disc","tb-500","ara-290","recovery-stack-intro"],"question":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","answer_preview":"Catalogue covers 2 explicit herniated-disc anecdotes under BPC-157 (global_id bpc-157:c5: one user with L4-L5 herniation reported reduced radicular pain after 8 weeks BPC-157 + PT; bpc-157:c6: one user reported nausea within two weeks and discontinued). Broader anecdotal tier (bpc-157:c101, c111 and others) mentions tissue/tendon healing or gut effects but does not reference discs. Multiple duplicate nausea reports (c122–c158) are low-weight repeats. No interaction_risk or limitations-slot claims are present for this condition. Recovery-stack-herniated-disc, bpc-ara-herniated-disc and ara-290-herniated-disc slugs are listed in the graph but supply no additional anecdote text in the provided topology.","confidence":"medium","status":"gap","parent_node_id":null,"gaps":["No dosing, duration, route, or imaging-confirmed outcomes are stated; long-term safety unknown (bpc-157:c67)."],"needs_user_info":[],"cited_claim_ids":["bpc-157:c5","bpc-157:c6","bpc-157:c101","bpc-157:c111","bpc-157:c120"],"cited_source_ids":[],"channel":"selftest","author":"graph_selftest","hash":"e1ae8e75c59f11910047c52a3155f64d7ed05a49899e8fd89d8806d7abe877be"},{"node_id":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_2926070f","ts":"2026-07-07T04:09:28.389Z","primary_slug":"bpc-157","slugs":["bpc-157","recovery-stack-herniated-disc","bpc-ara-herniated-disc","ara-290-herniated-disc","tb-500","ara-290","recovery-stack-intro"],"question":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","answer_preview":"Catalogue covers BPC-157 (bpc-157) with one L4-L5 herniation anecdote (reduced radicular pain after 8 weeks + PT, n=1) plus general tendon/muscle healing preclinical claims; recovery-stack-herniated-disc and bpc-ara-herniated-disc slugs exist but contain no populated claims on stacks for herniated discs; TB-500 appears only in one combined anecdotal claim for systemic tissue/tendon healing (not disc-specific); ARA-290 slugs exist with no disc claims; limitations slot (c120) and long-term safety unknown (c67) must be cited first. Gaps: no human data on disc healing, no interaction_risk data, no dosing information, no stack protocols, no imaging-confirmed outcomes.","confidence":"low","status":"gap","parent_node_id":null,"gaps":["no human disc-healing studies","no stack protocols in topology","no interaction data","no long-term safety data","anecdotes are n=1 only"],"needs_user_info":["specific disc level(s) and symptoms","current medications or conditions","prior imaging or diagnosis details","what the person has already tried"],"cited_claim_ids":["c120","c67","c5","c111","c1","c3"],"cited_source_ids":["s1","s3"],"channel":"selftest","author":"graph_selftest","hash":"4b2cfff6a6977daf02ed643b65a37f0a37c54ba778bade9010dbeb895be47e8e"}],"evidence":[{"ingest_id":"ev_c80ff6a253ba","ts":"2026-06-29T11:04:30.643Z","slug":"tb-500","question_node_id":null,"channel":"collaborate","author":"gemini/gemini-2.5-flash","summary":"As Gemini, I've added three tier-honest claims to address explicit gaps in knowledge (what_is_unknown) and clarify the status of ongoing research, using only provided source IDs. I also challenged an unsourced, overstrong claim regarding age-related decline.","source_ids":[],"claim_ids":["c33","c34","c35"],"model":"gemini/gemini-2.5-flash","hash":"d2a5764a0efbeceb119a8f0c986fd68300be3aa9cd4fb3a138b96dfcf3281438","status":"promoted"},{"ingest_id":"ev_7b3d01af4c49","ts":"2026-06-29T11:01:12.671Z","slug":"tb-500","question_node_id":null,"channel":"collaborate","author":"kimi/moonshot-v1-8k","summary":"I added explicit gaps in knowledge and named who claims what from anecdotes as instructed, as I am not Grok and my role is to contribute to the ledger with tier-honest claims.","source_ids":[],"claim_ids":["c30","c31"],"model":"kimi/moonshot-v1-8k","hash":"305c1e5d46709458e62575f3cf7a318075ff46751f145bcbfd65b3bd3397ebc1","status":"promoted"}],"edges":[{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_5f127446","to":"s1","type":"cites_source"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_5f127446","to":"s2","type":"cites_source"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_5f127446","to":"s3","type":"cites_source"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_5f127446","to":"s4","type":"cites_source"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_5f127446","to":"c1","type":"cites_claim"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_5f127446","to":"c2","type":"cites_claim"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_5f127446","to":"c3","type":"cites_claim"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_5f127446","to":"c4","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_241eb02b","to":"c5","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_241eb02b","to":"c120","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_241eb02b","to":"c67","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_50c640ac","to":"bpc-157:c5","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_50c640ac","to":"bpc-157:c111","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_50c640ac","to":"bpc-157:c120","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_50c640ac","to":"bpc-157:c67","type":"cites_claim"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_1b217ea4","to":"s1","type":"cites_source"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_1b217ea4","to":"s3","type":"cites_source"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_1b217ea4","to":"s4","type":"cites_source"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_1b217ea4","to":"s2","type":"cites_source"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_1b217ea4","to":"c1","type":"cites_claim"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_1b217ea4","to":"c3","type":"cites_claim"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_1b217ea4","to":"c4","type":"cites_claim"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_1b217ea4","to":"c2","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_7d3887e7","to":"bpc-157:c5","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_7d3887e7","to":"bpc-157:c6","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_7d3887e7","to":"bpc-157:c101","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_7d3887e7","to":"bpc-157:c111","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_5f30a319","to":"c5","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_5f30a319","to":"c67","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_5f30a319","to":"c111","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_5f30a319","to":"c120","type":"cites_claim"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_6e5d6ef8","to":"s1","type":"cites_source"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_6e5d6ef8","to":"c1","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_4527b1d6","to":"bpc-157:c5","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_4527b1d6","to":"bpc-157:c6","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_4527b1d6","to":"bpc-157:c120","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_4527b1d6","to":"bpc-157:c67","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","to":"s1","type":"cites_source"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","to":"s3","type":"cites_source"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","to":"s25","type":"cites_source"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","to":"s58","type":"cites_source"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","to":"c120","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","to":"c67","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","to":"c5","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","to":"c6","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","to":"c1","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","to":"c3","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","to":"c30","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_149821d9","to":"c76","type":"cites_claim"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_db376414","to":"s1","type":"cites_source"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_db376414","to":"s2","type":"cites_source"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_db376414","to":"c1","type":"cites_claim"},{"from":"qn_tb_500_selftest_graph_what_is_documented_about_t_db376414","to":"c2","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_cb92603c","to":"bpc-157:c5","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_cb92603c","to":"bpc-157:c6","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_cb92603c","to":"bpc-157:c101","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_cb92603c","to":"bpc-157:c111","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_cb92603c","to":"bpc-157:c120","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_2926070f","to":"s1","type":"cites_source"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_2926070f","to":"s3","type":"cites_source"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_2926070f","to":"c120","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_2926070f","to":"c67","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_2926070f","to":"c5","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_2926070f","to":"c111","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_2926070f","to":"c1","type":"cites_claim"},{"from":"qn_bpc_157_selftest_graph_i_have_herniated_discs_wh_2926070f","to":"c3","type":"cites_claim"}],"counts":{"questions":12,"evidence":2,"edges":66}},"honesty":{"active_claims":10,"retracted_claims":0,"cut_claims":0,"challenges":2,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":10,"claims_total":10,"sources":20,"anecdotal":3,"scientific":15,"user_reports":0,"questions":12,"evidence_ingests":2}}